Home / Newsroom / Spravato PR



Waterbury Hospital Behavioral Health is now offering Spravato® therapy, a new and highly effective treatment for patients suffering with depression.

Spravato® (esketamine) is the first prescription nasal spray, taken with an oral antidepressant, which is FDA-approved for adults with treatment-resistant depression. Treatment-resistant depression (TRD) presents as depression in patients struggling with major depressive disorder and who have not responded adequately to two or more antidepressants. Depressive symptoms in adults with major depressive disorder (MDD) include suicidal thoughts.

On treatment days patients will administer Spravato® nasal spray themselves in a supervised clinical setting. After administering Spravato®, there is an observation period of approximately two hours.  Patients can receive their therapy comfortably and conveniently at the Waterbury Hospital clinic, ensuring their safety and wellbeing throughout the process while being monitored for rare potential side effects.

Waterbury Hospital is the first behavioral health provider in greater Waterbury to offer Spravato therapy.

“This treatment will allow us to help patients facing great challenges with treatment-resistant depression,” said Dr. Joseph Podolski, Vice President and Director of Behavioral Health and Addiction Services at Waterbury HEALTH.

To make a referral or for more information please call 203-573-6756 or 203-573-7048.

About Waterbury HEALTH

Waterbury HEALTH, which includes Waterbury Hospital, Alliance Medical Group, Cardiology Associates of Greater Waterbury, VNA Health at Home and Access Rehab Centers, Greater Waterbury Imaging Center, offers comprehensive healthcare services including primary care, emergency and acute care, and home healthcare. Serving Waterbury and eleven surrounding communities in Western Connecticut, Waterbury HEALTH is a member of Prospect Medical Holdings, Inc., a national family of hospitals and healthcare networks.